OA13170A - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. - Google Patents

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. Download PDF

Info

Publication number
OA13170A
OA13170A OA1200500329A OA1200500329A OA13170A OA 13170 A OA13170 A OA 13170A OA 1200500329 A OA1200500329 A OA 1200500329A OA 1200500329 A OA1200500329 A OA 1200500329A OA 13170 A OA13170 A OA 13170A
Authority
OA
OAPI
Prior art keywords
formula
compound
group
compounds
pyrazolo
Prior art date
Application number
OA1200500329A
Other languages
English (en)
French (fr)
Inventor
Maria Gabriella Brasca
Roberto D Alessio
Daniele Fancelli
Ron Ferguson
Achille Panzeri
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of OA13170A publication Critical patent/OA13170A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
OA1200500329A 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. OA13170A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22

Publications (1)

Publication Number Publication Date
OA13170A true OA13170A (en) 2006-12-13

Family

ID=33476970

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500329A OA13170A (en) 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.

Country Status (36)

Country Link
US (8) US7482354B2 (me)
EP (1) EP1636236B1 (me)
JP (1) JP5043432B2 (me)
KR (1) KR101084871B1 (me)
CN (2) CN102079746A (me)
AP (1) AP2064A (me)
AR (2) AR044543A1 (me)
AU (1) AU2004240772B2 (me)
BR (2) BR122019010200B8 (me)
CA (1) CA2526578C (me)
CO (1) CO5721006A2 (me)
CR (1) CR8102A (me)
CY (1) CY1114708T1 (me)
DK (1) DK1636236T3 (me)
EA (1) EA010904B1 (me)
EC (1) ECSP056194A (me)
ES (1) ES2436524T3 (me)
GE (1) GEP20094664B (me)
HR (1) HRP20050967B8 (me)
IL (1) IL172046A (me)
IS (1) IS2939B (me)
ME (1) ME00142B (me)
MX (1) MXPA05012573A (me)
MY (1) MY142019A (me)
NO (1) NO334992B1 (me)
NZ (1) NZ543661A (me)
OA (1) OA13170A (me)
PL (1) PL1636236T3 (me)
PT (1) PT1636236E (me)
RS (2) RS52899B (me)
SI (1) SI1636236T1 (me)
TN (1) TNSN05298A1 (me)
TW (1) TWI349672B (me)
UA (1) UA80763C2 (me)
WO (1) WO2004104007A1 (me)
ZA (1) ZA200509486B (me)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636236B1 (en) 2003-05-22 2013-10-09 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2390237T3 (es) 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
KR20090007635A (ko) * 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
UA102219C2 (ru) * 2006-12-21 2013-06-25 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
ES2527696T3 (es) * 2006-12-21 2015-01-28 Nerviano Medical Sciences S.R.L. Derivados de pirazoloquinazolina sustituidos, procedimientos para su preparación y su uso como inhibidores de la quinasa
CA2703489A1 (en) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2231656A1 (en) * 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
DK2303891T3 (en) * 2008-06-26 2016-05-30 Servier Lab PYRAZOLO-quinazolines as modulators of protein kinase-ACTIVITY
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP5677296B2 (ja) * 2008-07-29 2015-02-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ グリオーマの治療のためのｃｄｋ阻害剤の使用
CA2739148A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
EP2376084B1 (en) * 2008-11-24 2013-07-17 Nerviano Medical Sciences S.r.l. CDK inhibitor for the treatment of mesothelioma
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
US8580793B2 (en) * 2009-03-20 2013-11-12 Nerviano Medical Services S.R.L. Use of kinase inhibitor for the treatment of thymoma
EP2421872B1 (en) * 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
AR076784A1 (es) 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
JP5851990B2 (ja) * 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
MX336731B (es) * 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
JP5997143B2 (ja) * 2010-07-30 2016-09-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
EP2619181A1 (en) 2010-09-23 2013-07-31 Syngenta Participations AG Novel microbiocides
SG10201508715YA (en) * 2010-10-25 2015-11-27 G1 Therapeutics Inc Cdk inhibitors
WO2012080990A1 (en) 2010-12-17 2012-06-21 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
JP5925808B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
AU2012230896B9 (en) 2011-03-23 2015-06-18 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
ES2724531T3 (es) 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
EP2807166B1 (en) * 2012-01-23 2016-04-06 Boehringer Ingelheim International GmbH 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
CN104870446B (zh) 2012-11-07 2019-08-13 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
RS59790B1 (sr) 2013-03-15 2020-02-28 G1 Therapeutics Inc Privremena zaštita normalnih ćelija tokom hemoterapije
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
USRE48974E1 (en) 2014-04-07 2022-03-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US10493046B2 (en) 2015-07-17 2019-12-03 Universite Paris Descartes 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
EP3484462B1 (en) 2016-07-15 2022-12-14 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
DK3505519T3 (da) * 2016-11-11 2022-02-07 Yangtze River Pharm Group Co Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin
EP3652177A1 (en) * 2017-07-11 2020-05-20 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazoline derivatives as choline kinase inhibitors
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
EP3666774B1 (en) * 2017-08-11 2022-05-11 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor
US20220363690A1 (en) * 2019-09-05 2022-11-17 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Isoxazolo[5,4-h]quinazoline compounds as protein kinase inhibitors
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN116528871A (zh) * 2020-12-31 2023-08-01 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
JP2024505714A (ja) * 2021-02-08 2024-02-07 メッドシャイン ディスカバリー インコーポレイテッド ５，６－ジドヒロチエノ［３，４－ｈ］キナゾリン系化合物
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
WO2023104178A1 (zh) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
ES2249270T3 (es) 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EE05405B1 (et) 2000-08-10 2011-04-15 Pharmacia Italia S.P.A. Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
WO2002014319A2 (en) 2000-08-11 2002-02-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2002048114A1 (en) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
EP1379524A2 (en) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Chromane derivatives, process for their preparation and their use as antitumor agents
AU2002331050A1 (en) * 2001-08-10 2003-02-24 Pharmacia Corporation Carbonic anhydrase inhibitors
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
ATE495741T1 (de) 2001-09-26 2011-02-15 Pfizer Italia Srl Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
AU2003225580A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
EP1636236B1 (en) 2003-05-22 2013-10-09 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
ES2527696T3 (es) * 2006-12-21 2015-01-28 Nerviano Medical Sciences S.R.L. Derivados de pirazoloquinazolina sustituidos, procedimientos para su preparación y su uso como inhibidores de la quinasa

Also Published As

Publication number Publication date
AU2004240772A1 (en) 2004-12-02
US20070185143A1 (en) 2007-08-09
PT1636236E (pt) 2013-12-16
US7482354B2 (en) 2009-01-27
US20150158876A1 (en) 2015-06-11
CA2526578C (en) 2012-01-24
US20130338148A1 (en) 2013-12-19
EA010904B1 (ru) 2008-12-30
US8981089B2 (en) 2015-03-17
AU2004240772B2 (en) 2011-04-28
BRPI0410563B1 (pt) 2020-12-01
HRP20050967B1 (hr) 2014-03-28
ZA200509486B (en) 2008-09-25
ME00142B (me) 2010-10-10
US10280176B2 (en) 2019-05-07
EP1636236B1 (en) 2013-10-09
HRP20050967B8 (hr) 2014-04-25
TW200505924A (en) 2005-02-16
ES2436524T3 (es) 2014-01-02
JP2007502851A (ja) 2007-02-15
US20090124605A1 (en) 2009-05-14
US9637497B2 (en) 2017-05-02
CO5721006A2 (es) 2007-01-31
HRP20050967A2 (en) 2007-05-31
US20170190714A1 (en) 2017-07-06
US8541429B2 (en) 2013-09-24
IL172046A (en) 2017-03-30
US20210300935A1 (en) 2021-09-30
PL1636236T3 (pl) 2014-02-28
AP2005003452A0 (en) 2005-12-31
IS8132A (is) 2005-11-18
NZ543661A (en) 2009-05-31
AR102722A2 (es) 2017-03-22
KR101084871B1 (ko) 2011-11-21
CA2526578A1 (en) 2004-12-02
BR122019010200B1 (pt) 2020-12-15
BRPI0410563B8 (pt) 2021-05-25
JP5043432B2 (ja) 2012-10-10
SI1636236T1 (sl) 2014-01-31
NO20055496D0 (no) 2005-11-21
AR044543A1 (es) 2005-09-21
BR122019010200B8 (pt) 2021-07-27
DK1636236T3 (da) 2013-12-09
CR8102A (es) 2006-08-09
MY142019A (en) 2010-08-16
US20170050972A1 (en) 2017-02-23
ECSP056194A (es) 2006-04-19
US9464090B2 (en) 2016-10-11
BRPI0410563A (pt) 2006-06-20
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
KR20060015294A (ko) 2006-02-16
RS20050944A (en) 2008-06-05
UA80763C2 (en) 2007-10-25
NO334992B1 (no) 2014-08-18
US20190194214A1 (en) 2019-06-27
NO20055496L (no) 2006-02-14
EP1636236A1 (en) 2006-03-22
IS2939B (is) 2016-03-15
CN102079746A (zh) 2011-06-01
MEP25908A (en) 2010-06-10
WO2004104007A1 (en) 2004-12-02
TNSN05298A1 (fr) 2007-07-10
GEP20094664B (en) 2009-04-10
AP2064A (en) 2009-10-30
RS52899B (en) 2014-02-28
MXPA05012573A (es) 2006-02-22
TWI349672B (en) 2011-10-01
CN1826343A (zh) 2006-08-30

Similar Documents

Publication Publication Date Title
OA13170A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
KR101223826B1 (ko) 키나제 억제제로서의 치환된 피롤로-피라졸 유도체
JP6181862B2 (ja) ピラゾロピロリジン誘導体および疾患の処置におけるその使用
JP2005529850A (ja) 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用
KR20150041787A (ko) 2,3-벤조디아제핀
EA028175B1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
WO2007071621A1 (en) Heteroarylpyrrolopyridinones active as kinase inhibitors